CompletedNot Applicable

Combined Use of a Novel Cardioplegic Formula With MPS ® Using the MiECC in Isolated CABG Versus OPCABG

Switzerland2,433 participantsStarted 2010-06-12

Plain-language summary

A patient group receiving a novel cardioplegic formula with MPS ® (Myocardial protection system) and using the MiECC (Minimal extracorporeal circulation system) when undergoing coronary artery bypass grafting is compared to a retrospective patient group undergoing Off-pump coronary artery bypass grafting.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * CABG using MPS® or OPCABG Exclusion Criteria: * use of other colloid solution than Cardioplexol ® for MPS® * other inventions than CABG * myocardial infarction \<7 days before CABG * patients denial of data use

What they're measuring

assessment of cardial biomarkers as high sensitive troponin T (hs-TrT), Creatinkinase (CK) and Creatinkinase myocardial type (CK-MB)

Timeframe: perioperative during hospital stay for CABG

Trial details

NCT IDNCT03609723

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-12-31

View on ClinicalTrials.gov More Complication of Coronary Artery Bypass Graft trials